	US 12,139,518 B2
	Compositions and methods for treating or preventing fibrosis
Choongseong Han, Seoul (KR); Dong-Hun Woo, Seoul (KR); Xiong Jin, Seoul (KR); Jaehun Lee, Seoul (KR); Geun Ho An, Seoul (KR); Tack Jin Yoo, Seoul (KR); and Jinwoo Chung, Seoul (KR)
Assigned to Nexel Co., Ltd., Seoul (KR)
Appl. No. 17/285,040
Filed by Nexel Co., Ltd., Seoul (KR)
PCT Filed Oct. 24, 2019, PCT No. PCT/IB2019/001136 § 371(c)(1), (2) Date Apr. 13, 2021, PCT Pub. No. WO2020/084344, PCT Pub. Date Apr. 30, 2020.
Claims priority of application No. 10-2018-0128033 (KR), filed on Oct. 25, 2018; application No. 10-2018-0128204 (KR), filed on Oct. 25, 2018; and application No. 10-2018-0128625 (KR), filed on Oct. 26, 2018.
Prior Publication US 2021/0388041 A1, Dec. 16, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 1/16 (2006.01); A61P 9/00 (2006.01); A61P 11/00 (2006.01); A61P 25/28 (2006.01); C12N 15/81 (2006.01)

CPC C07K 14/47 (2013.01) [A61P 1/16 (2018.01); A61P 9/00 (2018.01); A61P 11/00 (2018.01); A61P 25/28 (2018.01); C12N 15/815 (2013.01); A61K 38/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/43 (2013.01)]

21 Claims

1. A pharmaceutical composition comprising a recombinant polypeptide that (a) lacks a medin polypeptide of MFG-E8, and (b) comprises an MFG-E8 polypeptide that has at least 90% sequence identity to:

(i) the amino acid residues 1-225 of SEQ ID NO: 10 or SEQ ID NO: 12; or

(ii) the amino acid residues 24-225 of SEQ ID NO: 10 or SEQ ID NO: 12,

wherein the MFG-E8 polypeptide is not glycosylated.